Literature DB >> 16637073

Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.

Z Wu1, M Conaway, D Gioeli, M J Weber, D Theodorescu.   

Abstract

BACKGROUND: Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is lost as a function of prostate tumor androgen dependence. While the transcriptional activity of the androgen receptor (AR) is inhibited by PTEN in androgen sensitive prostate cancer (CaP), the role of PTEN in androgen disease is unclear.
METHODS: We developed a system where PTEN can be conditionally re-expressed at physiologic levels into a PTEN null metastatic human CaP cell line, C4-2, and androgen responsiveness examined.
RESULTS: PTEN induction reduces cell growth and blocks the growth effect of synthetic androgen R1881. The anti-androgen Casodex enhances the growth-inhibitory action of PTEN and this effect is independent of Akt phosphorylation. Combined PTEN induction and Casodex, result in a further decrease in prostate specific antigen promoter activity compared to PTEN but not Casodex alone.
CONCLUSIONS: PTEN induction confers androgen independent CaP cells enhanced responsiveness to the anti-proliferative effects of anti-androgens and this action may involve non-AR mediated effects. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16637073     DOI: 10.1002/pros.20447

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  14 in total

1.  The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.

Authors:  Sanjay N Mediwala; Huiying Sun; Adam T Szafran; Sean M Hartig; Guru Sonpavde; Teresa G Hayes; Perumal Thiagarajan; Michael A Mancini; Marco Marcelli
Journal:  Prostate       Date:  2012-07-20       Impact factor: 4.104

2.  Regulation of phosphatase homologue of tensin protein expression by bone morphogenetic proteins in prostate epithelial cells.

Authors:  Travis J Jerde; Zhong Wu; Dan Theodorescu; Wade Bushman
Journal:  Prostate       Date:  2010-11-04       Impact factor: 4.104

Review 3.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

Review 4.  Metastasis-suppressor genes in clinical practice: lost in translation?

Authors:  Alexander N Shoushtari; Russell Z Szmulewitz; Carrie W Rinker-Schaeffer
Journal:  Nat Rev Clin Oncol       Date:  2011-04-26       Impact factor: 66.675

5.  Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.

Authors:  Z Wu; D Gioeli; M Conaway; M J Weber; D Theodorescu
Journal:  Prostate       Date:  2008-06-15       Impact factor: 4.104

Review 6.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

Review 7.  Metastasis suppressor genes.

Authors:  Jinchun Yan; Qin Yang; Qihong Huang
Journal:  Histol Histopathol       Date:  2013-03       Impact factor: 2.303

8.  Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis.

Authors:  Zhong Wu; HyungJun Cho; Garret M Hampton; Dan Theodorescu
Journal:  Neoplasia       Date:  2009-01       Impact factor: 5.715

9.  Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study.

Authors:  Soha Salama El Sheikh; Hanna M Romanska; Paul Abel; Jan Domin; El-Nasir Lalani
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

10.  PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.

Authors:  Khalil Choucair; Joshua Ejdelman; Fadi Brimo; Armen Aprikian; Simone Chevalier; Jacques Lapointe
Journal:  BMC Cancer       Date:  2012-11-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.